ArticleBMC cancer2026
Immune checkpoint inhibitor-related efficacy in non-small cell lung cancer: real-world incidence and management practices of 208 patients.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundNon-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality, with most cases diagnosed at advanced stages. Immune checkpoint inhibitors (ICIs), especially PD-1/PD-L1 inhibitors, have transformed treatment paradigms, yet real-world data on their efficacy and post-progression strategies remain limited.
methodsThis retrospective cohort study analyzed 208 patients with advanced NSCLC, of whom 104 received chemotherapy alone and 104 received chemo-immunotherapy. The primary endpoint was progression-free survival (PFS); overall survival (OS) was secondary. Kaplan–Meier analysis, log-rank tests, and Cox proportional hazards models were employed. Subgroup analyses assessed the impact of metastatic sites, smoking status, and adverse events.
resultsCombination therapy significantly improved median PFS (9.7 vs. 3.7 months; P < 0.001) and OS (17.8 vs. 10.3 months; P < 0.001) compared to chemotherapy alone. The 3-year OS rate was notably higher in the combination group (31.7% vs. 12.2%). Poor ECOG status, lymph node metastases, and single-agent chemotherapy were linked to shorter PFS in the chemotherapy group. In the combination group, smoking, liver metastases, and severe adverse events were independent predictors of worse PFS. Among patients receiving second-line treatment, prior PD-1 inhibitor exposure was associated with longer PFS but not OS.
conclusionIn this retrospective real-world cohort of advanced NSCLC, ICIs combined with chemotherapy were associated with longer PFS and OS compared with chemotherapy alone, although residual confounding due to baseline imbalances and the non-randomized design cannot be excluded. These findings support the use of chemo-immunotherapy in appropriate patients and highlight the need for personalized, biomarker-driven strategies to address resistance and improve post-progression management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.